Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Cocaine Dependence
Interventions: SYN115, PLACEBO; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: DNA Damage, Psychological Stress
Interventions: Propranolol, Placebo oral capsule, Acute stress task, No stress task; Drug · Behavioral
Lead sponsor: Dana Bovbjerg; Other
Eligibility: 20 Years to 59 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Huntington's Disease
Interventions: VX15/2503, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more

Conditions: Weight Gain
Interventions: Zonisamide, olanzapine, Sugar Pill (placebo); Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Hepatitis C
Interventions: GSK2336805 150mg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Migraine Prophylaxis
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more

Conditions: Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Interventions: RGLS8429, Placebo; Drug
Lead sponsor: Regulus Therapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more

Conditions: Norovirus Infections
Interventions: VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pain
Interventions: Acetaminophen/naproxen sodium Dose A, Acetaminophen/naproxen sodium Dose B, Acetaminophen/naproxen sodium Dose C, Acetaminophen/naproxen sodium Dose D, Acetaminophen/naproxen sodium Dose E, Placebo; Drug
Lead sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division; Industry
Eligibility: 17 Years to 50 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Sitaxentan sodium/Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Infertility, Female
Interventions: Follitropin delta, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more

Conditions: Hearing Loss, Sensorineural
Interventions: PF-04958242, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Anaheim, California • New Haven, Connecticut • South Miami, Florida + 2 more

Conditions: Healthy
Interventions: PF-04965842, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID cp ΔM2-2 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Gastroenteritis Norovirus
Interventions: Norovirus GII.4 Challenge Pool CIN-1, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more

Conditions: Influenza
Interventions: MEDI8852, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Oxidative Stress
Interventions: Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: placebo, SEP-363856, metformin; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Oakland Park, Florida • Marlton, New Jersey

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 55
States / cities: Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more

Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Interventions: Efinopegdutide, Placebo; Combination Product
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more

Conditions: Decision Making, Executive Function, Dopamine
Interventions: Tolcapone 200 MG, Functional Magnetic Resonance Imaging (fMRI); Drug · Other
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Staphylococcal Infection
Interventions: Cephalexin, Clindamycin, Placebo, Trimethoprim-sulfamethoxazole; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 2 more

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 with Matrix M-2, GEN-003, Placebo; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cincinnati, Ohio + 4 more

Search by objective public record fields.

An fMRI Study of SYN115 in Cocaine Dependent Subjects

Brief Stresses Experimental Study

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Norovirus Challenge Study

Acetaminophen/Naproxen Sodium Dose Ranging Study

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Dopaminergic Mechanisms Underlying Human Social Behavior

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine